Oncotarget

Research Papers:

Peripheral lymphocyte subset variation predicts prostate cancer carbon ion radiotherapy outcomes

Zhang-Ru Yang, Ning Zhao, Jin Meng, Ze-Liang Shi, Bing-Xin Li, Xian-Wei Wu, Ping Li, Qing Zhang, Xun-Bin Wei and Shen Fu _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:26422-26435. https://doi.org/10.18632/oncotarget.8389

Metrics: PDF 1778 views  |   HTML 2390 views  |   ?  


Abstract

Zhang-Ru Yang1,2,*, Ning Zhao2,*, Jin Meng2,*, Ze-Liang Shi2, Bing-Xin Li2, Xian-Wei Wu3, Ping Li3, Qing Zhang3, Xun-Bin Wei1, Shen Fu2,3

1State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China

2Department of Radiation Oncology, Shanghai Sixth People’s Hospital of Jiao Tong University, Shanghai, China

3Radiation Oncology Center, Fudan University Shanghai Cancer Center (FUSCC), Shanghai Proton and Heavy Ion Center (SPHIC), Shanghai, China

*These authors have contributed equally to this work

Correspondence to:

Shen Fu, email: [email protected]

Xun-Bin Wei, email: [email protected]

Keywords: carbon ion radiotherapy, prostate cancer, peripheral lymphocyte

Received: November 04, 2015    Accepted: February 29, 2016    Published: March 26, 2016

ABSTRACT

The immune system plays a complementary role in the cytotoxic activity of radiotherapy. Here, we examined changes in immune cell subsets after heavy ion therapy for prostate cancer. The lymphocyte counts were compared with acute radiotherapy-related toxicity, defined according to the Common Terminology Criteria for Adverse Events, and short-term local efficacy, defined based on prostate-specific antigen concentrations. Confirmed prostate cancer patients who had not received previous radiotherapy were administered carbon ion radiotherapy (CIR) in daily fractions of 2.74 GyE with a total dose of 63-66 GyE. Lymphocyte subset counts were investigated before, during and after radiotherapy, and at a 1 month follow-up. Most notable among our findings, the CD4/CD8 ratio and CD19+ cell counts were consistently higher in patients with a complete response (CR) or partial response (PR) to CIR than in those classified in the stable disease (SD) group (P<0.05 for both). But CD3+ and CD8+ cell counts were lower in the CR and PR groups than in the SD group. These results indicate that variations in peripheral lymphocyte subpopulations are predictive of outcome after CIR for prostate cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8389